The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Steroid Response in Refractory Asthmatics

  • Jang, An-Soo (Department of Internal Medicine, Soonchunhyang University Bucheon Hospital)
  • Published : 2012.06.01
⟨ Previous Next ⟩

Abstract

Inhaled glucocorticosteroids are currently the most effective anti-inflammatory controller medications for treating persistent asthma. The efficacies of glucocorticoids include reducing asthma symptoms, reducing exacerbation frequency, improving quality of life, improving lung function, decreasing airway hyperresponsiveness, controlling airway inflammation, and reducing mortality. However, the treatment response to glucocorticosteroids in asthmatics varies, and certain subtypes of asthma, such as refractory asthma, respond poorly to high-dose inhaled glucocorticoid and systemic steroids. The medical costs of treating refractory asthmatics represent about 50% of the total healthcare cost for asthma. A thorough understanding of the mechanisms of glucocorticoid action, patient responses to glucocorticoids, and steroid resistance observed in refractory asthmatics is necessary for the targeted development of therapeutic drugs. This review discusses the characteristics of severe refractory asthmatics and the mechansms of steroid response and resistance in asthma treatment.

Keywords

References

  1. The Korean Academy of Asthma, Allergy and Clinical Immunology. Treatment 2007 Korea adult asthma treatment guideline [Internet]. Seoul (KR): The Korean Academy of Asthma, Allergy and Clinical Immunology, c2005 [cited 2012 Mar 20]. Available from: http://www.allergy.or.kr.
  2. The Korean Academy of Asthma, Allergy and Clinical Immunology. Treatment guideline of asthma in Korea [Internet]. Seoul (KR): The Korean Academy of Asthma, Allergy and Clinical Immunology, c2005 [cited 2012 Mar 20]. Available from: http://www.allergy.or.kr.
  3. National Heart, Lung, and Blood Institute. Guidelines for the diagnosis and management of asthma (EPR-3) [Internet]. Bethesda (MD): National Heart, Lung, and Blood Institute, 2007 [cited 2012 Mar 20]. Available from: http://www.nhlbi. nih.gov/guidelines/asthma.
  4. James AL, Maxwell PS, Pearce-Pinto G, Elliot JG, Carroll NG. The relationship of reticular basement membrane thickness to airway wall remodeling in asthma. Am J Respir Crit Care Med 2002;166(12 Pt 1):1590-1595. https://doi.org/10.1164/rccm.2108069
  5. Chetta A, Foresi A, Del Donno M, Bertorelli G, Pesci A, Olivieri D. Airways remodeling is a distinctive feature of asthma and is related to severity of disease. Chest 1997;111:852-857. https://doi.org/10.1378/chest.111.4.852
  6. Reed CE. The natural history of asthma in adults: the problem of irreversibility. J Allergy Clin Immunol 1999;103:539-547. https://doi.org/10.1016/S0091-6749(99)70221-6
  7. Ten Hacken NH, Postma DS, Timens W. Airway remodeling and long-term decline in lung function in asthma. Curr Opin Pulm Med 2003;9:9-14. https://doi.org/10.1097/00063198-200301000-00002
  8. Wenzel S. Mechanisms of severe asthma. Clin Exp Allergy 2003;33:1622-1628. https://doi.org/10.1111/j.1365-2222.2003.01799.x
  9. Wenzel S. Severe/fatal asthma. Chest 2003;123(3 Suppl):405S-410S.
  10. Wenzel S. Severe asthma: epidemiology, pathophysiology and treatment. Mt Sinai J Med 2003;70:185-190.
  11. Heaney LG, Robinson DS. Severe asthma treatment: need for characterizing patients. Lancet 2005;365:974-976. https://doi.org/10.1016/S0140-6736(05)71087-4
  12. Heaney LG, Conway E, Kelly C, et al. Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol. Thorax 2003;58:561-566. https://doi.org/10.1136/thorax.58.7.561
  13. Stirling RG, Chung KF. Severe asthma: definition and mechanisms. Allergy 2001;56:825-840. https://doi.org/10.1034/j.1398-9995.2001.00143.x
  14. Afzal M, Tharratt RS. Mechanical ventilation in severe asthma. Clin Rev Allergy Immunol 2001;20:385-397. https://doi.org/10.1385/CRIAI:20:3:385
  15. Robinson DS, Campbell DA, Durham SR, et al. Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003;22:478-483. https://doi.org/10.1183/09031936.03.00017003
  16. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions: American Thoracic Society. Am J Respir Crit Care Med 2000;162:2341-2351. https://doi.org/10.1164/ajrccm.162.6.ats9-00
  17. Barnes PJ, Woolcock AJ. Difficult asthma. Eur Respir J 1998;12:1209-1218. https://doi.org/10.1183/09031936.98.12051209
  18. Chung KF, Godard P, Adelroth E, et al. Difficult/therapyresistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. Eur Respir J 1999;13:1198-1208.
  19. Chu HW, Trudeau JB, Balzar S, Wenzel SE. Peripheral blood and airway tissue expression of transforming growth factor beta by neutrophils in asthmatic subjects and normal control subjects. J Allergy Clin Immunol 2000;106:1115-1123. https://doi.org/10.1067/mai.2000.110556
  20. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003;22:470-477. https://doi.org/10.1183/09031936.03.00261903
  21. Tillie-Leblond I, Gosset P, Tonnel AB. Inflammatory events in severe acute asthma. Allergy 2005;60:23-29. https://doi.org/10.1111/j.1398-9995.2005.00632.x
  22. National Asthma Education and Prevention Program. National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics-2002. J Allergy Clin Immunol 2002;110(C):S141-S219. https://doi.org/10.1016/S0091-6749(02)80002-1
  23. Sandford AJ, Chagani T, Zhu S, et al. Polymorphisms in the IL4, IL4RA, and FCERIB genes and asthma severity. J Allergy Clin Immunol 2000;106(1 Pt 1):135-140. https://doi.org/10.1067/mai.2000.107926
  24. Spiteri MA, Bianco A, Strange RC, Fryer AA. Polymorphisms at the glutathione S-transferase, GSTP1 locus: a novel mechanism for susceptibility and development of atopic airway inflammation. Allergy 2000;55 Suppl 61:15-20. https://doi.org/10.1034/j.1398-9995.2000.00502.x
  25. Chu HW, Balzar S, Westcott JY, et al. Expression and activation of 15-lipoxygenase pathway in severe asthma: relationship to eosinophilic phenotype and collagen deposition. Clin Exp Allergy 2002;32:1558-1565. https://doi.org/10.1046/j.1365-2222.2002.01477.x
  26. Szalai C, Kozma GT, Nagy A, et al. Polymorphism in the gene regulatory region of MCP-1 is associated with asthma susceptibility and severity. J Allergy Clin Immunol 2001;108:375-381. https://doi.org/10.1067/mai.2001.117930
  27. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160:1001-1008. https://doi.org/10.1164/ajrccm.160.3.9812110
  28. Jang AS, Lee JH, Park SW, et al. Factors inf luencing the responsiveness to inhaled glucocorticoids of patients with moderate-to-severe asthma. Chest 2005;128:1140-1145. https://doi.org/10.1378/chest.128.3.1140
  29. Vignola AM, Mirabella F, Costanzo G, et al. Airway remodeling in asthma. Chest 2003;123(3 Suppl):417S-422S.
  30. Jeffery PK, Wardlaw AJ, Nelson FC, Collins JV, Kay AB. Bronchial biopsies in asthma: an ultrastructural, quantitative study and correlation with hyperreactivity. Am Rev Respir Dis 1989;140:1745-1753. https://doi.org/10.1164/ajrccm/140.6.1745
  31. Takeyama K, Fahy JV, Nadel JA. Relationship of epidermal growth factor receptors to goblet cell production in human bronchi. Am J Respir Crit Care Med 2001;163:511-516. https://doi.org/10.1164/ajrccm.163.2.2001038
  32. Carroll NG, Mutavdzic S, James AL. Distribution and degranulation of airway mast cells in normal and asthmatic subjects. Eur Respir J 2002;19:879-885. https://doi.org/10.1183/09031936.02.00275802
  33. Barnes PJ. Corticosteroids: the drugs to beat. Eur J Pharmacol 2006;533:2-14. https://doi.org/10.1016/j.ejphar.2005.12.052
  34. Leung DY, Hamid Q, Vottero A, et al. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J Exp Med 1997;186:1567-1574. https://doi.org/10.1084/jem.186.9.1567
  35. Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med 2005;172:149-160. https://doi.org/10.1164/rccm.200409-1181PP
  36. Barnes PJ. Corticosteroid resistance in airway disease. Proc Am Thorac Soc 2004;1:264-268.
  37. Chung KF. Individual cytokines contributing to asthma pathophysiology: valid targets for asthma therapy? Curr Opin Investig Drugs 2003;4:1320-1326.
  38. Barnes PJ. New drugs for asthma. Nat Rev Drug Discov 2004;3:831-844. https://doi.org/10.1038/nrd1524
  39. Hedley ML. Gene therapy of chronic inflammatory disease. Adv Drug Deliv Rev 2000;44:195-207. https://doi.org/10.1016/S0169-409X(00)00095-8
  40. Bryan SA, Leckie MJ, Hansel TT, Barnes PJ. Novel therapy for asthma. Expert Opin Investig Drugs 2000;9:25-42. https://doi.org/10.1517/13543784.9.1.25
  41. Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008;372:1073-1087. https://doi.org/10.1016/S0140-6736(08)61449-X

Cited by

  1. Glucocorticoid-resistant asthma: more than meets the eye vol.50, pp.10, 2013, https://doi.org/10.3109/02770903.2013.831870
  2. The role of rhinosinusitis in severe asthma vol.28, pp.6, 2013, https://doi.org/10.3904/kjim.2013.28.6.646
  3. Refractory asthma: mechanisms, targets, and therapy vol.69, pp.7, 2014, https://doi.org/10.1111/all.12412
  4. Pharmacotherapy of Critical Asthma Syndrome: Current and Emerging Therapies vol.48, pp.1, 2012, https://doi.org/10.1007/s12016-013-8393-8
  5. Effects of combinatorial in vitro stimulation with glucocorticoids and vitamin D3 on the expression of Foxp3 in CD4+ T cells of healthy individuals vol.2, pp.3, 2012, https://doi.org/10.1016/j.alergo.2015.08.005
  6. Effects of genetic polymorphisms in Vitamin D metabolic pathway on Vitamin D level and asthma control in South Indian patients with bronchial asthma vol.36, pp.6, 2019, https://doi.org/10.4103/lungindia.lungindia_23_19
  7. Azelastine potentiates antiasthmatic dexamethasone effect on a murine asthma model vol.7, pp.6, 2019, https://doi.org/10.1002/prp2.531
  8. Drug Repurposing to Treat Glucocorticoid Resistance in Asthma vol.11, pp.3, 2012, https://doi.org/10.3390/jpm11030175
  9. Severe asthma and eligibility for biologics in a Brazilian cohort vol.58, pp.7, 2012, https://doi.org/10.1080/02770903.2020.1748049
  10. A GATA3 Targeting Nucleic Acid Nanocapsule for In Vivo Gene Regulation in Asthma vol.15, pp.7, 2012, https://doi.org/10.1021/acsnano.0c07781